Brand-name Ozempic and Wegovy are FDA-approved medications manufactured by Novo Nordisk
The increasing prevalence of obesity worldwide and its associated pressure on healthcare systems, along with the reputation of GLP-1 drugs for inducing significant weight loss (approximately 1525+%, significantly higher than previous generations of obesity drugs), are driving GLP-1 drug expansion into new markets like China
Triumphing over adioposity Moving onto the obesity trial, Triumph-1
These medications may indirectly improve insulin sensitivity through weight loss and improved glycaemic control
In mice, intragastric administration of a mixture of BTR agonists (including DB, phenylthiocarbamide (PTC), quinine and D-[-]salicin) was shown to increase plasma total ghrelin and octanoyl ghrelin levels without affecting ghrelin mRNA expression (55)
The starting dose is deliberately conservative to allow for this dual adaptation